3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
fludarabine phosphate
23
Cyclophosphamide
23
Peripheral Blood Stem Cell Transplantation
22
Antilymphocyte Serum
18
Busulfan
16
Tacrolimus
15
Mycophenolic Acid
15
Cyclosporine
14
Methotrexate
11
Filgrastim
11
Whole-Body Irradiation
10
Methylprednisolone
9
Melphalan
9
Sirolimus
6
Radiotherapy
6
Psychiatric Rehabilitation
6
Etoposide
6
Cord Blood Stem Cell Transplantation
6
sargramostim
4
Flow Cytometry
4
Early Intervention, Educational
4
Polymerase Chain Reaction
3
Epoetin Alfa
3
Darbepoetin alfa
3
Thiotepa
2
Therapeutics
2
Rituximab
2
Ondansetron
2
Moxifloxacin
2
Morphine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts